Published in Clin Cancer Res on March 09, 2010
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer (2012) 3.55
Obesity and cancer. Oncologist (2010) 3.01
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer (2011) 1.80
The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev (2012) 1.75
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One (2015) 1.46
Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control (2012) 1.26
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer (2013) 1.25
Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiol Biomarkers Prev (2013) 1.25
Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol (2011) 1.15
Obesity in cancer survival. Annu Rev Nutr (2012) 1.13
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. Cancer (2014) 1.12
Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst (2013) 1.11
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol (2011) 1.11
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A (2014) 1.09
Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg (2013) 1.07
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol (2011) 0.98
Oncohematological diseases in the Vale do Paraíba, State of São Paulo: demographic aspects, prevalences and incidences. Rev Bras Hematol Hemoter (2011) 0.98
Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) (2013) 0.97
Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev (2015) 0.95
Lifestyle factors associated with survival after colorectal cancer diagnosis. Br J Cancer (2013) 0.95
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol (2015) 0.93
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol (2013) 0.93
Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst (2012) 0.90
Role of body mass index in colon cancer patients in Taiwan. World J Gastroenterol (2012) 0.90
Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis. Tech Coloproctol (2016) 0.90
Obesity does not affect survival outcomes in extremity soft tissue sarcoma. Clin Orthop Relat Res (2014) 0.87
Diet and lifestyle in survivors of colorectal cancer. Hematol Oncol Clin North Am (2015) 0.85
Obesity was associated with a decreased postoperative recurrence of rectal cancer in a Japanese population. Surg Today (2014) 0.85
Association of body mass index and smoking on outcome of Chinese patients with colorectal cancer. World J Surg Oncol (2013) 0.84
The Association between Polymorphismsin Insulin and Obesity Related Genesand Risk of Colorectal Cancer. Iran J Cancer Prev (2013) 0.82
Analysis of the impact of the body mass index in patients with gastric carcinoma. Surg Today (2012) 0.82
Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer (2015) 0.82
Impact of body mass index on survival of esophageal squamous carcinoma patients in southern China. J Thorac Dis (2015) 0.81
Obesity and colorectal cancer. Clin Colon Rectal Surg (2011) 0.80
Does body mass index impact the number of LNs harvested and influence long-term survival rate in patients with stage III colon cancer? Int J Colorectal Dis (2012) 0.79
Leptin and peroxisome proliferator-activated receptor γ expression in colorectal adenoma. World J Gastroenterol (2012) 0.79
Preoperative Body Mass Index, Blood Albumin and Triglycerides Predict Survival for Patients with Gastric Cancer. PLoS One (2016) 0.79
Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage-specific associations. Int J Cancer (2016) 0.79
The Association between Obesity and Colorectal Cancer. Gastroenterol Res Pract (2012) 0.78
Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. Br J Cancer (2015) 0.78
Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer (2013) 0.77
Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol (2016) 0.77
Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. Clin Epigenetics (2015) 0.77
Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Med (2015) 0.77
Obesity, insulin and chemoresistance in colon cancer. J Gastrointest Oncol (2011) 0.77
Impact of Diet, Body Mass Index, and Physical Activity on Cancer Survival. Curr Nutr Rep (2012) 0.76
Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams. JAMA Oncol (2016) 0.76
Comparative effectiveness of strategies to prevent weight gain among women with and at risk for breast cancer: a systematic review. Springerplus (2013) 0.76
Adipose-derived stem cells promote tumor initiation and accelerate tumor growth by interleukin-6 production. Oncotarget (2015) 0.76
Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. BMC Cancer (2015) 0.75
NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. Oncotarget (2016) 0.75
Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. World J Surg Oncol (2015) 0.75
Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis. Int J Mol Sci (2017) 0.75
Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore) (2016) 0.75
Prediagnostic body weight and survival in high grade glioma. J Neurooncol (2013) 0.75
Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study. BMC Cancer (2016) 0.75
Prognostic Impact of Changes in Adipose Tissue Areas after Colectomy in Colorectal Cancer Patients. J Korean Med Sci (2016) 0.75
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. Oncologist (2016) 0.75
Underweight status predicts a poor prognosis in elderly patients with colorectal cancer. Mol Clin Oncol (2016) 0.75
Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis (2017) 0.75
3'UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients. PLoS One (2016) 0.75
Changes in Adult BMI and Waist Circumference Are Associated with Increased Risk of Advanced Colorectal Neoplasia. Dig Dis Sci (2017) 0.75
Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy. Oncol Lett (2017) 0.75
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep (2016) 0.75
Impact of Increased Visceral Fat Measured by CT on Colon Adenocarcinoma Stage. J Gastrointest Cancer (2016) 0.75
Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser (1995) 57.68
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA (2004) 25.36
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA (2007) 11.50
Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med (1992) 10.44
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med (1995) 5.42
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr (2001) 5.16
Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest (1983) 4.70
Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst (2006) 4.17
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr (2007) 3.66
Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst (2000) 3.57
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst (2002) 3.32
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr (2007) 3.20
Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007) 3.16
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst (2006) 2.77
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol (2008) 2.63
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst (1997) 2.46
Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst (1999) 2.40
Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut (2005) 2.37
Physical inactivity, excess adiposity and premature mortality. Obes Rev (2003) 2.32
BMI and mortality: results from a national longitudinal study of Canadian adults. Obesity (Silver Spring) (2009) 2.25
A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer (2003) 2.19
Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) (2006) 2.17
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2005) 2.15
Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins. Br J Nutr (2007) 2.14
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev (2000) 2.12
Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol (2000) 1.91
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol (2008) 1.88
BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord (2004) 1.85
Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol (2007) 1.73
Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res (2001) 1.67
Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. Eur J Cancer (2006) 1.64
Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control (2005) 1.55
Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep (2003) 1.48
A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg (2002) 1.48
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology (1993) 1.45
Body size and colorectal-cancer risk. Int J Cancer (1998) 1.34
Obesity in youth and middle age and risk of colorectal cancer in men. Cancer Causes Control (1992) 1.27
Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res (1989) 1.26
Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 1.23
Body mass index and colon cancer in a national sample of adult US men and women. Am J Epidemiol (1999) 1.22
HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res (2000) 1.20
Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology (1992) 1.18
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer (2006) 1.18
Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol (2009) 1.11
Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol (2006) 1.05
The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology (1992) 0.97
Are leptin levels dependent on body fat distribution in obese men and women? Eat Weight Disord (1998) 0.78
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol (2009) 5.69
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg (2007) 5.30
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol (2007) 4.60
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol (2009) 4.09
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2009) 3.38
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 3.08
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol (2004) 2.98
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol (2011) 2.88
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol (2006) 2.81
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst (2006) 2.77
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol (2008) 2.58
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol (2009) 2.47
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 2.34
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol (2009) 2.32
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol (2005) 2.28
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. Ann Surg (2008) 2.19
An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med (2006) 2.16
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery (2005) 2.10
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology (2006) 2.02
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol (2009) 1.83
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol (2007) 1.77
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Cyclodextrin-threaded conjugated polyrotaxanes as insulated molecular wires with reduced interstrand interactions. Nat Mater (2002) 1.66
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol (2002) 1.65
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol (2011) 1.64
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol (2013) 1.62
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol (2004) 1.61
Saturated linkage map construction in Rubus idaeus using genotyping by sequencing and genome-independent imputation. BMC Genomics (2013) 1.61
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest (2008) 1.56
Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer (2008) 1.54
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics (2011) 1.54
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst (2010) 1.53
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol (2009) 1.53
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol (2010) 1.47
Alternate endpoints for screening phase II studies. Clin Cancer Res (2009) 1.47
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol (2012) 1.46
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J Clin Oncol (2004) 1.46
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol (2013) 1.46
Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43
Development of a dense SNP-based linkage map of an apple rootstock progeny using the Malus Infinium whole genome genotyping array. BMC Genomics (2012) 1.42
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol (2010) 1.40
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer (2011) 1.38
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol (2006) 1.34
An evaluation of the PacBio RS platform for sequencing and de novo assembly of a chloroplast genome. BMC Genomics (2013) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol (2008) 1.30